News | December 17, 2025
Glenmark secures exclusive multi-regional rights to Aumolertinib from Hansoh Pharma
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
MRI is particularly valuable in pediatric care due to its non-invasive nature
Subscribe To Our Newsletter & Stay Updated
